Effects of CYP2C9 polymorphism on the pharmacokinetics of irbesartan in healthy Korean subjects

被引：0
|
作者：
Kim, Mi-Jung
Bae, Jung -Woo
Han, Ho-Kyun
Choi, Sun-Ok
Kim, Ok-Hee
Jang, Choon-Gon
Lee, Jin-Hee
Kim, Nam-Tae
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
Irbesartan; CYP2C9; polymorphism; pharmacokinetics;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [11] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Pureum Kang
    Chang-Keun Cho
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Chang-Ik Choi
    Jung-Woo Bae
    Archives of Pharmacal Research, 2023, 46 : 438 - 447
  • [12] Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects
    Sabia, H
    Sunkara, G
    Ligueros-Saylan, M
    Wang, YB
    Smith, H
    McLeod, J
    Prasad, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (06) : 407 - 412
  • [13] Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects
    Helene Sabia
    Gangadhar Sunkara
    Monica Ligueros-Saylan
    Yibin Wang
    Harold Smith
    James McLeod
    Pratapa Prasad
    European Journal of Clinical Pharmacology, 2004, 60 : 407 - 412
  • [14] Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics
    Lee, H. W.
    Lim, M. -S.
    Lee, J.
    Jegal, M. -Y.
    Kim, D. -W.
    Lee, W. -K.
    Jang, I. -J.
    Shin, J. -G.
    Yoon, Y. -R.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (01) : 105 - 111
  • [15] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Lu, Sijie
    Nand, R. A.
    Yang, J. S.
    Chen, Gang
    Gross, A. S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 285 - 296
  • [16] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Sijie Lu
    R. A. Nand
    J. S. Yang
    Gang Chen
    A. S. Gross
    European Journal of Clinical Pharmacology, 2018, 74 : 285 - 296
  • [17] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Cho, Chang-Keun
    Byeon, Ji-Young
    Kang, Pureum
    Park, Hye-Jung
    Ko, Eunvin
    Mu, Chou Yen
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (02) : 111 - 116
  • [18] The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    Bo Tan
    Yi-Fan Zhang
    Xiao-Yan Chen
    Xiao-Hua Zhao
    Guo-Xin Li
    Da-Fang Zhong
    European Journal of Clinical Pharmacology, 2010, 66 : 145 - 151
  • [19] The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    Tan, Bo
    Zhang, Yi-Fan
    Chen, Xiao-Yan
    Zhao, Xiao-Hua
    Li, Guo-Xin
    Zhong, Da-Fang
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (02) : 145 - 151
  • [20] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Chang‑Keun Cho
    Ji-Young Byeon
    Pureum Kang
    Hye-Jung Park
    Eunvin Ko
    Chou Yen Mu
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2023, 46 : 111 - 116
12345